SCHEMBL10132609

SCHEMBL10132609

O=C(NCCc1cnc[nH]1)c1ccc2c(c1)[nH]c(=O)c1ccsc12

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 4/20 0.54
CSNK2A1 P68400 2/20 0.54
CSNK2A2 P19784 1/20 0.54
CSNK2B P67870 1/20 0.54
CYP3A4 P08684 1/20 0.52
KMT2A Q03164 1/20 0.51
NAMPT P43490 4/20 0.48
MYC P01106 1/20 0.47
CDK1 P06493 1/20 0.47
CDK2 P24941 1/20 0.47
BRD4 O60885 1/20 0.43
QPCT Q16769 1/20 0.42
QPCTL Q9NXS2 1/20 0.42
PBK Q96KB5 1/20 0.41
HTR3E A5X5Y0 1/20 0.41
HTR3B O95264 1/20 0.41
HTR3A P46098 1/20 0.41
HTR3D Q70Z44 1/20 0.41
HTR3C Q8WXA8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10132647 0.81 PARP1 (0.66) PARP1CSNK2A1CSNK2A2CSNK2BKMT2A
SCHEMBL10132620 0.80 PARP1 (0.64) PARP1CSNK2A1CSNK2A2CSNK2BKMT2A
SCHEMBL10132666 0.79 PARP1 (0.66) PARP1CSNK2A1CSNK2A2CSNK2BKMT2A
SCHEMBL13687980 0.79 PARP1 (0.62) PARP1CSNK2A1CSNK2A2CSNK2BKMT2A
SCHEMBL10132622 0.79 PARP1 (0.54) PARP1CSNK2A1CSNK2A2CSNK2BKMT2A
SCHEMBL10132625 0.79 PARP1 (0.61) PARP1CSNK2A1CSNK2A2CSNK2B
SCHEMBL10132580 0.78 PARP1 (0.60) PARP1CSNK2A1CSNK2A2CSNK2BKMT2A
SCHEMBL10132626 0.77 ALDH1A1 (0.63) PARP1CSNK2A1CSNK2A2CSNK2BCYP3A4
SCHEMBL10132659 0.77 PARP1 (0.69) PARP1CSNK2A1CSNK2A2CSNK2B
SCHEMBL10132650 0.77 PARP1 (0.59) PARP1CSNK2A1CSNK2A2CSNK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9062043-B2 Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators SENHWA BIOSCIENCES, INC. (TW) 2015-06-23 US disclosed
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-20110263581-A1 FUSED TRICYCLIC COMPOUNDS AS SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2011-10-27 US disclosed
US-7956064-B2 Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators CYLENE PHARMACEUTICALS, INC. (US) 2011-06-07 US disclosed
US-7956064-B2 Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators CYLENE PHARMACEUTICALS, INC. (US) 2011-06-07 US disclosed
US-20090264423-A2 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-10-22 US disclosed
US-20090264423-A2 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-10-22 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed
WO-2009108912-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-09-03 WO disclosed
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-04-23 US disclosed
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-04-23 US disclosed
WO-2008028168-A2 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2008-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263581-A1 FUSED TRICYCLIC COMPOUNDS AS SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS PARP1, PARP11, TNKS PARP1 1/4885CSNK2A1 66/4885CSNK2A2 90/4885
US-20090264423-A2 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS PACSIN2, TNKS, PARP1 PARP1 3/4885CSNK2A1 24/4885CSNK2A2 37/4885
US-20120208792-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 PARP1 690/4885CSNK2A1 680/4885CSNK2A2 810/4885
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS PACSIN2, TNKS, PARP1 PARP1 3/4885CSNK2A1 24/4885CSNK2A2 37/4885
US-20090239859-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 PARP1 690/4885CSNK2A1 680/4885CSNK2A2 810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.